The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone

BJU International

Volumn 102, Issue 5, 2008, Pages 551-555

  Saad, Fred ^a,b   Ruether, Dean ^c   Ernst, Scott ^e   North, Scott ^d   Cheng, Tina ^c   Perrotte, Paul ^b   Karakiewicz, Pierre ^b   Winquist, Eric ^e  

^a NOTRE DAME HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Docetaxel; Drug therapy; Mitoxantrone; Pain; Phase II; Prostatic neoplasms

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABDOMINAL ABSCESS; ADULT; AGED; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; BONE MARROW SUPPRESSION; BONE PAIN; CANADA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEATH; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FLANK PAIN; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MALE; MELENA; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; MYOPATHY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY FAILURE; SEPTIC SHOCK; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TOOTH DISEASE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PAIN; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 48749086947     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07733.x     Document Type: Article

References (21)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Available at: http://www.cancer.ca/vgn/images/portal/ cit_86755361/36/17/1816216953cw_2007stats_fr.pdf
2. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999 27 : 62 73
3. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994 331 : 996 1004
4. Vogelzang NJ. One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 1995 14 : 1753 5
5. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996 14 : 1756 64
6. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999 17 : 2506 13
7. Picus J, Schultz M. A phase II trial of docetaxel in patients with hormone refractory prostate cancer. Long term results. Proc Am Soc Clin Oncol 1999 18 : 1206
8. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999 17 : 958 67
9. Natale RB, Zaretsky S. Phase I/II trial of estramustine and Taxotere in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999 18 : 1343
10. Savarese DM, Taplin ME, Marchesani B et al. A Phase II trial of docetaxel, estramustine, and low dose hydrocortisone in hormone refractory prostate cancer: CALGB 9780. Proc Am Soc Clin Oncol 1999 18 : 1234
11. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. A Phase II study evaluating a one day course of estramustine phosphate and docetaxel, in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999 18 : 1239
12. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999 10 : 33 8
13. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
14. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 251 : 1502 12
15. Melzack R. The McGill pain questionnaire. Major properties and scoring methods. Pain 1975 1 : 277 99
16. Van Andel G, Kurth KH, De Haes JC. Quality of life in patients with prostatic carcinoma; a review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life. Urol Res 1997 25 (Suppl. 2 S79 88
17. Sommers DS, Ramsey SD. A review of quality of life evaluations in prostate cancer. Pharmacoeconomics 1999 16 : 127 40
18. Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC. Results of a randomized phase III trial. J Clin Oncol 2007 25 (Suppl. 5019
19. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006 106 : 1041 6
20. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006 67 : 1235 40
21. Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 2005 35 : 468 72